Figure and table legends
FIGURE 1. Study scheme. The patients were selected into or
excluded from the study according to the scheme. Representative
photographs of C3 immunofluorescence staining. Bar=50μm.
FIGURE 2. Glomerular immunodeposits from the patients in
C3low and C3high group. (A, B, D, E,
G and H) Representative photographs of glomerular immune
complexes deposition (IgA, IgG and IgM) from C3low and
C3high group. Bar=50μm. (C, F and I)The difference of glomerular immune complexes deposition (IgA, IgG and
IgM) in C3low and C3high group.
Glomerular IgA deposition was graded by IgA=2+ and IgA>2+;
Glomerular IgG, IgM deposition was graded by absent (score, 0), mild
(score, 1), severe (score, 2), respectively. The difference of
constituent ratio was analyzed by Chi square test.
FIGURE 3. Morphological characteristics of the biopsies from the
patients in C3low and C3high group.(A-F) Representative photographs of PAS staining, Masson
staining and electron microscopy from C3low and
C3high group. Bar=50μm. The magnification by electron
microscopy was 2000 times.
FIGURE 4. C3high group contained more
lymphocytes in C3low group in IgAN renal biopsies.A, B, D, E, G, H represent photographs of
CD68+, CD4+ and
CD8+ cells in C3low and
C3high groups. C, F, I showed renal tissues
were revealed more CD68+, CD4+ and
CD8+ cells infiltration in the
C3high group. Box plots indicated statistical
differences. Values greater than 95% or less than 5% is listed as a
dot while values less than 95% or greater than 5% were hidden in
positive and negative error line. The line in the center of each box
represents the median value, and the upper and lower ends of the box are
the upper and lower quartiles, Bar=50μm.
FIGURE 5. Renal survival curve of creatinine doubling and ESRD.
(A) Kaplan-Meier estimates of proportion of renal survival (absence of
creatinine doubling) in 83.3% (85/102) v.s. 61.8% (21/34) of the
patients in C3low and C3high group,
respectively. Estimated overall survival time were 97.8 (95%
CI:93.4-102.2) months for patients in C3low group; 81.9 (95% CI:
70.7–93.0) months for patients in C3high group,
P=0.025 (log rank test). (B) Kaplan-Meier estimates of
proportion of renal survival (absence of ESRD) in 93.1 % (95/102) v.s.
67.6% (23/34) of the patients in C3low and
C3high group, respectively. Estimated survival time
were 100.2 (95% CI: 96.4-104.1) months for patients in
C3low group; 86.5 (95% CI: 75.9–97.0) months for
patients C3high group, P=0.002 (log rank test).